Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Fig. 7

5-FU plus PEPDG278D-based combination treatment inhibits orthotopic CRC. a Tumor burden measured by bioluminescence imaging. Tumor-bearing mice were treated by EP daily (days 22–56), or EP daily plus aderbasib daily (days 26–56) plus PEPDG278D thrice weekly (days 27–55) plus 5-FU every 3–4 days (days 28–56). EP, PEPDG278D and 5-FU were administered to mice by ip at 0.5, 4 and 35 mg/kg per dose, respectively. Aderbasib was administered to mice by gavage at 60 mg/kg per dose. Each value is mean ± SEM (n = 11–12). **P < 0.01 by Mann-Whitney U test. b-d Percentage of mice showing frank primary tumors, average tumor weight, and percentage of mice showing liver metastasis at the end of experiment. e Western blotting of tumor homogenates (2 tumors per group). Tumors were harvested on day 57. See Fig. 1 and Fig. 2 legends for protein phosphorylation sites

Back to article page